Zoetis IncZTS
▼ NegativeDemandrelevance
Sales of Librela face headwinds from safety perception concerns among veterinarians, and next-gen product launches are delayed.
Impact on stocks 1
Health Care
Zoetis IncZoetis Inc., an animal health company, saw its shares decline sharply in the second quarter of 2026 following a downward revision to its near-term earnings guidance, as highlighted in the Impax US Sustainable Economy Fund's Q2 2026 investor letter. The stock closed at $75.81 per share on September 4, 2026, with a market capitalization of $31.33 billion, and while it returned 1.31% over the past month, it is down 50.04% over the past year. The fund noted that sales of Librela, Zoetis's key canine arthritis pain management product, continued to face headwinds from safety perception concerns among some veterinarians, and management indicated that the ramp-up of next-generation product launches would extend into the following year. Impax US Sustainable Economy Fund, which outperformed the Russell 1000 in Q2 2026, holds Zoetis for its attractive sustainability opportunity profile and strong governance, but the stock's decline was a drag on the portfolio's performance.
Zoetis IncSales of Librela face headwinds from safety perception concerns among veterinarians, and next-gen product launches are delayed.